In today’s Pharmaceutical Executive Daily, we explore why medical AI success depends on more than algorithms, Amgen’s launch of its new direct-to-consumer platform AmgenNow, and AstraZeneca’s ...
FDA approves Jascayd, the first new treatment for idiopathic pulmonary fibrosis in over a decade, significantly reducing ...
The deadline for DSCSA compliance is approaching. For many in the industry, this moment marks the end of a long regulatory ...
Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition.
Pharma companies have the choice of facing strict tariffs or negotiating with the current administration. Pharmaceutical Executive: How will pharma companies react to the administration's efforts? Dr.
Shauna Tetrald, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into ...
In today’s Pharmaceutical Executive Daily, we cover the FDA lifting its clinical hold on Neurizon Therapeutics’ lead program Nuz-001, the agency’s export ban on Sun Pharma’s Halol facility, and new ...
Algen Biotechnologies partners with AstraZeneca to enhance AI-driven drug discovery, targeting chronic inflammatory ...
Chiesi Group partners with Arbor Biotechnologies to advance gene editing therapies for rare diseases, focusing on primary hyperoxaluria type 1.
Amgen introduces AmgenNow, a direct-to-patient program for Repatha, offering affordable access to life-saving cardiovascular ...
With ever-increasing costs to put a single molecule on the market, the pressure to reach clinical milestones quickly and ...
Stay informed on key pharmaceutical news, including FDA insights, Takeda's strategic shifts, and updated CDC COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback